Symbols

CTSO

Cytosorbents·NASDAQ

--(--)

CTSO fundamentals

CTSO Q4 2025 Earnings

Cytosorbents (CTSO) released its earnings on Mar 25, 2026: revenue was 9.23M (YoY +0.37%), missed estimates; EPS was -0.07 (YoY +50.00%), missed estimates.

Revenue / YoY

9.23M

+0.37%

EPS / YoY

-0.07

+50.00%

Report date

Mar 25, 2026

CTSO Earnings Call Summary for Q4,2025

Revenue Growth: 4% YoY to $37.1M, driven by international expansion (13% direct, 11.4% distributor) despite Germany decline.
Profitability: Gross margin 71% (74% Q4), with path to cash flow breakeven in H2 2026 via cost cuts and inventory optimization.
Innovation Momentum: 100+ PuriFi units placed globally; HotSwap gains strong clinician feedback.
FDA Progress: Streamlined DrugSorb-ATR resubmission expected post-FDA alignment; STAR-T trial validation published.
Germany Recovery: Restructured sales team shows early signs of improvement with Q1 pipeline activity.

Earnings

EPS

Revenue

Revenue & Expenses

CTSO has released its 2025 Q4 earnings report, with revenue of 9.23M, reflecting a YoY change of 0.91%, and net profit of -5.50M, showing a YoY change of 27.36%. The Sankey diagram below clearly presents CTSO's revenue sources and cost distribution.

Key Indicators

Cytosorbents (CTSO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cytosorbents (CTSO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Cytosorbents (CTSO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Cytosorbents (CTSO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown